Flu kills tens of thousands of Americans every year, and existing vaccines have never been particularly impressive. So the FDA’s approval of Moderna’s mFLUSIVA, the first mRNA-based influenza vaccine, is worth paying attention to. The agency approved the shot on August 5, 2026, for adults aged 50 and older, clearing the way for distribution ahead of the 2026-2027 respiratory season.
What the trial data showed
Approval for adults aged 50 to 64 rests on a Phase 3 trial of 40,805 participants across 11 countries. The study measured relative vaccine efficacy against RT-PCR-confirmed influenza compared to a standard-dose comparator. For adults 65 and older, approval was granted under the FDA’s accelerated pathway, based on immunogenicity data from a separate 2,992-person U.S. trial benchmarked against a high-dose inactivated flu vaccine. A confirmatory postmarketing trial is still required for that older age group. The safety profile across both studies was consistent with earlier mFLUSIVA research, with no new concerns flagged.
Why this matters beyond the flu shot
This is Moderna’s fifth approved product globally and its fourth in the U.S., joining Spikevax, mRESVIA, and mNEXSPIKE. More broadly, it signals that mRNA-based vaccines are moving into routine, non-emergency immunization. If mFLUSIVA demonstrates strong real-world efficacy in older adults, it could pressure the wider flu vaccine market and accelerate regulatory confidence in mRNA platforms for other infectious diseases.
Availability and global outlook
Moderna expects supply to reach select U.S. retailers within weeks. Regulatory reviews are already underway in the European Union, Canada, and Australia, with additional submissions planned through 2026.
- Approved for adults 50 and older in the U.S.
- 65+ approval is accelerated, pending confirmatory trial results
- Phase 3 enrolled 40,805 adults across 11 countries
- Under regulatory review in the EU, Canada, and Australia
For clinicians advising older patients this fall, mFLUSIVA is now a legitimate option. But given the accelerated approval status for the 65-plus group, it’s worth watching the postmarketing data closely before drawing firm conclusions about comparative effectiveness in that population.